You are here

Article Text

Article menu
Download PDFPDF
Research letter
Starting anticoagulation for atrial fibrillation in the emergency department safely

https://doi.org/10.1136/emermed-2022-212487

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Edward Carlton

    • Twitter @XC_TongMD

    • Contributors The study was designed by KdW. The study was conducted by CW, SR, JC, XCT, JH, NC, RMcA and AK. Analysis was performed by KdW and all authors helped draft the manuscript.

    • Funding This hospital programme is partly funded by a grant from Bayer (Bayer manufacture rivaroxaban, which is an anticoagulant used in the prevention of stroke for patients with atrial fibrillation).

    • Provenance and peer review Not commissioned; externally peer reviewed.